2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

3222 Age and cell-type specific mechanisms of leukemic transformation in pre-B cells expressing ETV6-RUNX1

Le'Mark Russell, Lynn White2, Haley Schmidt, PhD3, Abby Green, MD4, Jeffrey Bednarski, MD, PhD5
1 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States, Washington University in Saint Louis, Saint Louis, Missouri, United States
2 Washington University in Saint Louis, Saint Louis, Missouri, United States
3 Washington University in Saint Louis, Saint Louis, Missouri, United States
4 Washington University in Saint Louis, Saint Louis, Missouri, United States
5 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States, Washington University in Saint Louis, Saint Louis, Missouri, United States

The ETV6-RUNX1 translocation is the most prevalent genomic aberration in pediatric precursor B cell acute lymphoblastic leukemia (pre-B ALL). Despite this, the molecular mechanism underlying how ETV6-RUNX1 leads to malignancy remains incompletely understood. ETV6-RUNX1 is a fusion protein that arises in hematopoietic progenitor cells as a translocation of the ETV6 and RUNX1 loci resulting in the N-terminal regulatory domain of ETV6 fused to the full length RUNX1. ETV6-RUNX1 translocations arise in utero during fetal hematopoiesis. Although ETV6 is expressed in all hematopoietic cells, leukemias with ETV6-RUNX1 translocations are exclusively of pre-B cell origin and occur uniquely in children, and not adults. Thus, B cell-specific and age-specific factors contribute to ETV6-RUNX1-driven leukemic transformation.

To investigate mechanisms of leukemogenesis, we used a conditional murine model for expressing ETV6-RUNX1 in which exons 6-7 of Etv6 have been replaced by a floxed stop cassette followed by the RUNX1 gene (Etv6RUNX1). When crossed with VavCre (VavCre:Etv6RUNX1), the stop cassette is removed and RUNX1 is spliced onto Exon 5 of Etv6 in hematopoietic cells. This experimental system mirrors human disease with expression of ETV6-RUNX1 controlled by endogenous Etv6 regulatory elements and expression in hematopoietic cells, including B cells. To investigate age-specific effects of ETV6-RUNX1 expression on pre-B cells, we isolated pre-B cells from fetal liver (E17.5) and adult (8-week-old) bone marrow of control Etv6RUNX1 (which do not express the transgene) and VavCre:Etv6RUNX1 mice then cultured them in IL-7 containing media. IL-7 promotes proliferation and expansion of pre-B cells. ETV6-RUNX1-expressing pre-B cells from adult mice had reduced expansion, proliferation, and viability compared to control adult pre-B cells. In contrast, ETV6-RUNX1-expressing pre-B cells from fetal liver had similar expansion and viability as fetal pre-B cells from control mice. Thus, expression of ETV6-RUNX1 is differentially deleterious to adult pre-B cells whereas fetal pre-B cells tolerate the fusion and continue to proliferate.

To further assess the effect of ETV6-RUNX1 on adult pre-B cells, we performed bulk RNA-sequencing on sorted large (proliferating) and small (G1-arrested) pre-B cells from adult control and VavCre:Etv6RUNX1 mice. Expression of ETV6-RUNX1 profoundly altered pre-B cell transcriptional programs. Specifically, pre-B cells expressing ETV6-RUNX1 had aberrant expression of inflammation-associated genes including Hmox1, Bcl6, and Spic. We next asked whether ETV6-RUNX1 affects gene expression through distinct mechanisms in early B cells. In this regard, pre-B cells uniquely undergo immunoglobulin (Ig) receptor gene recombination. This process is mediated by the RAG endonuclease which generates double-stranded DNA breaks (DSBs) necessary for Ig gene assembly. RAG-mediated DSBs activate the DNA damage response kinase ATM, which in turn triggers a B cell-specific transcriptional program that coordinates pre-B cell development. We hypothesized that RAG DSB-mediated signaling influenced effects of ETV6-RUNX1 on pre-B cell gene expression. To test this, we expressed ETV6-RUNX1 in RAG-deficient and ATM-deficient pre-B cells, which do not generate RAG DSBs or activate DSB-dependent signaling, respectively. ETV6-RUNX1-mediated induction of inflammation-associated genes did not occur in pre-B cells lacking RAG or ATM. These findings demonstrate that ETV6-RUNX1 drives inflammatory gene programs in pre-B cells in a manner dependent on RAG DSB-mediated cellular signals.

Our results show that ETV6-RUNX1 synergizes with B cell-specific DNA damage signaling to mediate gene expression changes in pre-B cells, which differentially impacts B cell development in an age-specific manner. Ongoing work will define the mechanisms underlying differential activity of ETV6-RUNX1 in fetal versus adult pre-B cells and the cooperative activity of RAG-induced DNA break signals and ETV6-RUNX1 in regulating expression of inflammatory genes in pre-B cells. Together these studies establish new insight into mechanisms that promote leukemic transformation in ETV6-RUNX1-expressing pediatric pre-B ALL.

Le'Mark Russell: No relevant conflicts of interest to declare.